EUCTR2014-003849-10-BG进行中（未招募）1 期
A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab (150 mg) in pre-filled syringe, with or without loading regimen, to demonstrate efficacy, safety and tolerability up to 2 years in patients with active psoriatic arthritis (FUTURE 4) - FUTURE 4
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 341
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Diagnosis of Psoriatic Arthritis (PsA) classified by ClASsification criteria for Psoriatic ARthritis (CASPAR) criteria
- •Rheumatoid factor and anti-cyclic citrullinated peptide (CCP) antibodies negative
- •Diagnosis of active plaque psoriasis or nail changes consistent with psoriasis
- •Inadequate control of symptoms with NSAID
- •Other protocoldefined inclusion criteria do apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 315
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 26
排除标准
- •Chest X-ray or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process
- •Subjects taking high potency opioid analgesics
- •Previous exposure to secukinumab or other biologic drug directly targeting interleukin-17 (IL-17) or IL-17 receptor
- •Ongoing use of prohibited psoriasis treatments / medications.
- •Subjects who have ever received biologic immunomodulating agents except for those targeting TNFa.
- •Previous treatment with any cell-depleting therapies
- •Other protocol-defined exclusion criteria do apply
研究者
相似试验
撤回
3 期
A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosisdisease of the central nervous system10007951multiple sclerosisNL-OMON30517Clinical Research Assistance25
进行中（未招募）
不适用
A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - Rebif FLEXible dosing in early Multiple Sclerosis (REFLEX)Subjects at high risk of converting to Multiple SclerosisMedDRA version: 9.0Level: PTClassification code 10028245EUCTR2006-002982-38-FIMerck Serono S.A. - Geneva, an affiliate of Merck KGaA Darmstadt, Germany480
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of bevacizumab in combination with chemotherapy in patients with breast cancer that spread to other tissues.HER2-negative metastatic breast cancer.MedDRA version: 18.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2011-005335-97-BGF. Hoffmann-La Roche Ltd480
进行中（未招募）
1 期
24 week efficacy and 3-year safety and efficacy of secukinumab in active Psoriatic ArthritisMedDRA version: 19.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859Psoriatic ArthritisEUCTR2013-004002-25-GBovartis Pharma Services AG417
进行中（未招募）
1 期
A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - Rebif FLEXible dosing in early Multiple Sclerosis (REFLEX)Subjects at high risk of converting to Multiple SclerosisMedDRA version: 9.0Level: PTClassification code 10028245EUCTR2006-002982-38-SKMerck Serono International, a branch of Laboratoires Serono SA An affiliate of Merck KGaA480